DGAP-News 508 0 Kommentare STADA Arzneimittel AG: Appointment of Dr. Matthias Wiedenfels extended

DGAP-News: STADA Arzneimittel AG / Key word(s): Contract
STADA Arzneimittel AG: Appointment of Dr. Matthias Wiedenfels extended

11.01.2016 / 09:55
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Vilbel, January 11, 2016 - On January 8, 2016, the Supervisory Board of
STADA Arzneimittel AG extended the appointment of Dr. Matthias Wiedenfels
as Chief Business Development & Central Services Officer by four years
until December 31, 2020. Dr. Wiedenfels has been a Member of STADA's
Executive Board since 2013. His previous contract would have ended on
December 31, 2016. Within the Executive Board, Dr. Wiedenfels is
responsible for the areas of Business Development, Portfolio Management,
Human Resources, Legal, IP/Patents, Compliance (including Export Control),
Risk Management, as well as for Quality Assurance and Quality Control.

"I'm very pleased about this repeated sign of confidence and about the
opportunity to continue the successful cooperation with my two colleagues
in the Executive Board in the coming years. In addition to the challenges
that lie ahead of us, we are also facing some great opportunities, which we
will take advantage of to pursue STADA's sustainable development goals.
This includes the further acceleration of the internationalization strategy
through value-enhancing acquisitions", says Dr. Wiedenfels about the plans
in connection with the extension of his contract.

The extension of the appointment of Dr. Wiedenfels and last year's
extension of the appointment of the Chairman of the Executive Board and the
Chief Financial Officer ensure the continued stability in the Executive
Board of STADA Arzneimittel AG. The STADA Executive Board continues to
consist of Hartmut Retzlaff, Chairman, Helmut Kraft, Chief Financial
Officer, and Dr. Matthias Wiedenfels, Chief Business Development & Central
Services Officer.

information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail:
ir@stada.de

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail:
press@stada.de

Or visit us in the Internet at http://www.stada.com.

---------------------------------------------------------------------------

11.01.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Munich, Stuttgart

End of News DGAP News Service
---------------------------------------------------------------------------

428177 11.01.2016